Display options
Cite
Saduqi M, Sharifi I, Babaei Z, et al. Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iran J Parasitol. 2019;14(4):521-533
Saduqi, M., Sharifi, I., Babaei, Z., Keyhani, A., Mostafavi, M., Hakimi Parizi, M., Ghasemian, M., Bamorovat, M., Sharifi, F., Aflatoonian, M. R., Sharififar, F., Ghasemi Nejad, P., Khosravi, A., Salarkia, E., & Varma, R. S. (2019). Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iranian journal of parasitology, 14(4), 521-533.
Saduqi, Morteza, et al. "Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on ." Iranian journal of parasitology vol. 14,4 (2019): 521-533.
Saduqi M, Sharifi I, Babaei Z, Keyhani A, Mostafavi M, Hakimi Parizi M, Ghasemian M, Bamorovat M, Sharifi F, Aflatoonian MR, Sharififar F, Ghasemi Nejad P, Khosravi A, Salarkia E, Varma RS. Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on . Iran J Parasitol. 2019 Oct-Dec;14(4):521-533. PMID: 32099555; PMCID: PMC7028242.
Copy Download .nbib Format: NLM
Share it on

Iran J Parasitol. 2019 Oct-Dec;14(4):521-533.

Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on .

Iranian journal of parasitology

Morteza Saduqi, Iraj Sharifi, Zahra Babaei, Alireza Keyhani, Mahshid Mostafavi, Maryam Hakimi Parizi, Mahdiyeh Ghasemian, Mehdi Bamorovat, Fatemeh Sharifi, Mohammad Reza Aflatoonian, Fariba Sharififar, Pooya Ghasemi Nejad, Ahmad Khosravi, Ehsan Salarkia, Rajender S Varma

Affiliations

  1. Department of Medical Parasitology and Mycology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
  2. Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
  3. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
  4. Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
  5. Herbal and Traditional Medicines Research Center, Department of Pharmacognosy, Kerman University of Medical Sciences, Kerman, Iran.
  6. Regional Center of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitel? 27, 783 71 Olomouc, Czech Republic.

PMID: 32099555 PMCID: PMC7028242

Abstract

BACKGROUND: Pentavalent antimonials such as meglumine antimoniate (MA, Glucantime), are the first-line treatment against leishmaniasis, but at present, they have basically lost their efficacy. This study was aimed to explore epigallocatechin 3-O-gallate (EGCG), alone or in combination with MA against

METHODS: All experiments were carried out in triplicate using colorimetric assay, macrophage model, flow cytometry and quantitative real-time PCR. This experimental study was carried out in 2017 in Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.

RESULTS: Promastigotes and amastigotes were more susceptible to EGCG than MA alone, but the effect was more profound when used in combination. EGCG exhibited high antioxidant level with a remarkable potential to induce apoptosis. Furthermore, the results showed that the level of gene expression pertaining to Th-1 was significantly up-regulated (

CONCLUSION: EGCG demonstrated a potent anti-leishmanial effect alone and more enhanced lethal activity in combination. The principal mode of action entails the stimulation of a synergistic response and up-regulation of the immunomodulatory role towards Th-1 response against

Copyright© Iranian Society of Parasitology & Tehran University of Medical Sciences.

Keywords: Apoptosis; Epigallocatechin 3-O-gallate; Gene expression; Immunomodulatory role; Leishmania tropica

Conflict of interest statement

Conflict of interests The authors declare that there is no conflict of interests.

References

  1. PLoS One. 2018 Feb 7;13(2):e0192236 - PubMed
  2. Planta Med. 2016 Mar;82(4):279-84 - PubMed
  3. EMBO J. 1985 Jun;4(6):1389-93 - PubMed
  4. J Ethnopharmacol. 2001 Dec;78(2-3):193-200 - PubMed
  5. PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3093 - PubMed
  6. Phytochemistry. 2006 Sep;67(18):2071-7 - PubMed
  7. PLoS One. 2012;7(8):e42070 - PubMed
  8. Cancer Res. 2006 Mar 1;66(5):2500-5 - PubMed
  9. Exp Parasitol. 2007 Oct;117(2):188-94 - PubMed
  10. J Nat Prod. 2013 Oct 25;76(10):1993-6 - PubMed
  11. Clin Microbiol Rev. 2006 Jan;19(1):111-26 - PubMed
  12. Parasitol Res. 2012 Mar;110(3):1113-7 - PubMed
  13. Gen Pharmacol. 1999 Jun;32(6):661-7 - PubMed
  14. PLoS Negl Trop Dis. 2017 Aug 10;11(8):e0005739 - PubMed
  15. J Biol Chem. 2004 Mar 19;279(12):11798-813 - PubMed
  16. Nat Rev Drug Discov. 2005 Sep;4(9):727-40 - PubMed
  17. PLoS One. 2011 Feb 08;6(2):e14666 - PubMed
  18. Exp Parasitol. 2012 Oct;132(2):151-5 - PubMed
  19. J Bacteriol. 1968 Jun;95(6):2131-8 - PubMed
  20. Int J Antimicrob Agents. 2009 Dec;34(6):596-601 - PubMed
  21. Cell Death Dis. 2015 Oct 22;6:e1933 - PubMed
  22. PLoS One. 2012;7(5):e35671 - PubMed
  23. J Med Chem. 1997 Aug 1;40(16):2634-42 - PubMed
  24. Methods Enzymol. 1999;299:15-27 - PubMed
  25. Mol Biochem Parasitol. 2003 Aug 11;130(1):31-42 - PubMed
  26. Annu Rev Pharmacol Toxicol. 2002;42:25-54 - PubMed
  27. Science. 2016 Jan 1;351(6268):84-8 - PubMed
  28. Antimicrob Agents Chemother. 2001 Jul;45(7):2023-9 - PubMed
  29. J Vector Borne Dis. 2014 Dec;51(4):294-9 - PubMed
  30. J Immunol. 1990 Aug 1;145(3):831-9 - PubMed
  31. Infect Immun. 1994 Apr;62(4):1414-20 - PubMed
  32. Infect Immun. 2005 Jul;73(7):3903-11 - PubMed
  33. Br J Pharmacol. 2013 Mar;168(5):1059-73 - PubMed

Publication Types